|
1. Biologie
|
|
|
Most of Human Genome Nonfunctional: Study [The Scientist]
|
|
|
|
|
|
The
estimate, generated by looking at fertility rates and the expected
frequency of deleterious mutations, contradicts a 2012 claim from a
large international group called ENCODE, which estimated that 80 percent
of the genome is functional.
|
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
New diagnostic tests: more harm than good [BMJ]
|
|
|
|
|
|
Although
new diagnostics may advance the time of diagnoses in selected patients,
they will increase the frequency of false alarms, overdiagnosis, and
overtreatment in others. Bjorn Hofmann and H. Gilbert Welch explain how
to minimise harm.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
AURAGEN, genome-sequencing platform at very high speed [HCL]
|
|
|
|
|
|
AURAGEN
is the very high speed sequencing platform project, a health-based
project built by the Auvergne Rhône-Alpes region within the plan France
Médecine Génomique 2025. It will allow entering the era of genomic
medicine with to a more personalized diagnostic and therapeutic care,
thanks to the routine sequencing of individual genomes.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
Kleo taps PeptiDream for help with immuno-oncology programs [FierceBiotech]
|
|
|
|
|
|
Kleo
focuses on two drug discovery platforms, Antibody-Recruiting Molecule
(ARM) and Synthetic Antibody Mimic (SyAM), which endeavor to engineer
small-molecule drugs that can mimic the effects of antibodies but are
much easier to manufacture, easier to deliver to patients and
potentially safer as they are less likely to cause immune reactions.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.6 Publications
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|